We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 56

Akzo Nobel fined $3.15 million for price fixing

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • November 24 2008

Canada's Competition Bureau announced on November 21, 2008 that Akzo Nobel Chemicals International BV had pled guilty to criminal charges for fixing the price of hydrogen peroxide sold in Canada between 1998 and 2001, and agreed to pay a C$3

Bureau releases generic drug sector study

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • November 15 2007

On October 29, 2007 the Competition Bureau (the Bureau) released its Canadian Generic Drug Sector Study, initiated in September, 2006, to identify areas where changes in the market framework might attain greater benefits through competition

Defendants may get reprieve from multiple and overlapping national class actions over Vioxx

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • December 19 2008

The issue of overlapping national class actions concerning the same causes of action will soon come before Ontario's appellate courts, thanks to a recent order granting leave to appeal in Mignacca v. Merck Frosst Canada

Commissioner strips Lululemon of clothing claims

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • December 18 2007

The Bureau announced on November 16, 2007 that Vancouver-based Lululemon Athletica Inc. has agreed to remove all claims alleging therapeutic benefits from its "VitaSea" line of clothing products, marketed in its forty retail stores across Canada

Proposed amendments to the Food and Drugs Act impose stricter after-market regulation on drugs and medical devices

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • May 20 2014

The Minister of Health has introduced Bill C-17 An Act to Amend the Food and Drugs Act in the House of Commons, which is currently at the second

Federal Court confirms decision to withhold designating notice of allegation as a confidential document

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • July 8 2010

Even though generic pharmaceutical companies invest significant time and funds into the preparation of notices of allegations (“NOA”s), the Federal Court has confirmed that such documents should remain available to the public and not be designated as confidential information under the terms of a protective order

Double patenting issue must be considered at time of hearing of application under the PM(NOC) regulations

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • July 8 2010

The Federal Court of Appeal rendered a decision that will have important implications on the litigation strategy of pharmaceutical companies

Federal Court confirms requirement of patent specificity for listing patents on the Patent Register

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • July 20 2010

Purdue Pharma sought judicial review of a decision of the Office of Patented Medicines and Liaison (OPML) in which the OPML determined that one of Purdue’s patents (the 738 Patent) was not eligible for listing on the Patent Register maintained in accordance with the Patented Medicines (Notice of Compliance) Regulations (Regulations) in respect of the drug TARGIN

If it sounds too good to be true

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • March 4 2010

Budget 2010 reads very well

Drug-related patent held invalid for double patenting and anticipation, but not obviousness

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • June 3 2010

In a decision rendered May 11, 2010 under the Patented Medicines (Notice of Compliance) Regulations, Justice Hughes of the Federal Court of Canada found Canadian Patent No. 2,173,457 (the ’457 Patent) to be invalid, and accordingly dismissed an application by Merck which sought to prohibit the Minister of Health from issuing a notice of compliance to Pharmascience, allowing Pharmascience to market its generic version of the medicine finasteride for treating male pattern baldness